The use of the CDK4/6 inhibitors palbociclib [186], ribociclib [187], and abemaciclib [188] as first- or second-line therapy confers survival benefits for patients with HR-positive/HER2-negative advanced breast cancer. This evidence concerns the gene ERBB2 and breast cancer.